Milestone Scientific insider sale: 10,000 shares disposed by director

Rhea-AI Filing Summary

BP4 S.r.l., listed as a director of Milestone Scientific Inc. (MLSS), reported a sale of 10,000 shares of the issuer's common stock on 09/11/2025 at a price of $0.594 per share. After the transaction the filing indicates beneficial ownership of 9,256,972 shares, held indirectly. The Form 4 was signed by Dr. Pedro Palau, Liquidator and filed on 09/15/2025. The filing shows a single non-derivative disposition and does not disclose any derivative transactions or a Rule 10b5-1 plan.

Positive

• None.

Negative

• Reported sale of 10,000 MLSS shares at $0.594 could be perceived negatively by some investors monitoring insider sales

Insights

Securities Analyst

TL;DR: Director reported a small open-market sale of 10,000 MLSS shares, leaving ~9.26M shares beneficially owned indirectly.

The reported sale of 10,000 shares at $0.594 appears as a routine insider disposition rather than a large, material divestiture given the remaining beneficial stake of 9,256,972 shares. The filing contains no derivatives, no purchase transactions, and no indication of a Rule 10b5-1 trading plan. For investors, this is a disclosure of insider activity required by Section 16; it does not on its face present a material change to ownership structure or control.

Corporate Governance Expert

TL;DR: Transaction is a straightforward Form 4 sale by an officer/director entity; documentation is complete and signed by a liquidator.

The Form 4 lists BP4 S.r.l. as the reporting person with a director relationship and is signed by Dr. Pedro Palau as Liquidator. The filing provides clear transaction details (date, code S, amount, and price) and post-transaction holdings, fulfilling disclosure obligations. There is no information in this filing indicating policy breaches, related-party transactions, or changes in board composition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BP4 S.r.l.

(Last) (First) (Middle)

CORSO VENEZIA 44

(Street)

MILAN L6 20121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MILESTONE SCIENTIFIC INC. [ MLSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, Par Value $0.001	09/11/2025		S		10,000	D	$0.594	9,256,972	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Dr. Pedro Palau, Liquidator	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the Form 4 for MLSS report?

The Form 4 reports a sale of 10,000 shares of Milestone Scientific Inc. common stock on 09/11/2025 at $0.594 per share.

Who filed the Form 4 for MLSS and what is their relationship to the company?

BP4 S.r.l. filed the Form 4 and is identified as a Director of Milestone Scientific Inc.; the form was signed by Dr. Pedro Palau, Liquidator.

How many MLSS shares were beneficially owned after the reported transaction?

9,256,972 shares were reported as beneficially owned following the sale, held indirectly.

Does the Form 4 disclose any derivative transactions or a trading plan?

No. The filing shows only a non-derivative disposition and does not disclose any derivative securities or a Rule 10b5-1 trading plan.